eFFECTOR’s Zotatifin (eFT226) Downregulates Key Oncogenic Driver Proteins Including RTKs (HER2, FGFR1 and FGFR2) Providing Single Agent Activity and Key Combination Opportunities

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy